SUBSCRIBE
SUBSCRIBE
News   Drug Development

Synosia Therapeutics Announces Positive Interim Results for Potential First-in-Class Treatment for Parkinson’s Disease

February 1, 2010 | 
1 min read
Bookmark and Share

BASEL, Switzerland--(BUSINESS WIRE)--Synosia Therapeutics today announced interim positive data from a Phase IIa clinical study of an adenosine 2a (A2a) receptor antagonist (SYN115) in Parkinson’s disease.
Clinical research Phase II Europe
MORE ON THIS TOPIC
Illustration showing woman starting down curved path with markers toward goal marked by flag
Rare diseases
New Confirmatory Study Hints at ‘Alignment’ Between Applied Therapeutics, FDA for Rare Disease Drug
September 29, 2025
 · 
2 min read
 · 
Tristan Manalac
2D illustration of kidneys
Immunology and inflammation
Hansa Kidney Transplant Drug Aces Phase III Study, Headed to FDA
September 26, 2025
 · 
2 min read
 · 
Tristan Manalac
Image of padlock on U.S. flag
Job Trends
$100,000 H-1B Fee Leaves Biopharma Grappling With Impact
September 25, 2025
 · 
6 min read
 · 
Angela Gabriel
Contemporary art collage of target and hands with the megaphone on a ue background with copy space. Concept of reaching a goal and spreading.
Pancreatic cancer
Immuneering Asset Nearly Doubles Overall Survival in Pancreatic Cancer After 9 Months
September 25, 2025
 · 
2 min read
 · 
Tristan Manalac